Homocysteine as a risk factor for cognitive impairment in stroke patients

Dementia and Geriatric Cognitive Disorders

Volumn 15, Issue 3, 2003, Pages 155-162

  Sachdev, Perminder S ^a,b   Valenzuela, Michael J ^a,b   Brodaty, Henry ^a,b   Wang, Xing Li ^a,b,c   Looi, Jeffrey ^a,b   Lorentz, Lisa ^a,b   Howard, Lesley ^b   Jones, Megan ^b   Zagami, Alessandro S ^a,b   Gillies, David ^b   Wilcken, David E L ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Brain scans; Cognitive impairment; Homocysteine; MRI; Total homocysteine

Indexed keywords

CREATININE; CYANOCOBALAMIN; FIBRINOGEN; FOLIC ACID; HOMOCYSTEINE;

ADULT; AGE; AGED; ARTICLE; ATTENTION; BRAIN ATROPHY; BRAIN FUNCTION; BRAIN SCINTISCANNING; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLIC ACID BLOOD LEVEL; HEART STROKE VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; STROKE; VITAMIN BLOOD LEVEL; WHITE MATTER;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; COGNITION DISORDERS; FEMALE; HOMOCYSTEINE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RISK FACTORS;

EID: 12244287634     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068481     Document Type: Article

References (51)

1. McCully KS: Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-128.
2. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I: Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 1991;324:1149-1155.
3. Kang SS, Wong PW, Malinow MR: Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992;12:279-298.
4. Mayer EL, Jacobsen DW, Robinson K: Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27:517-527.
5. Ueland PM, Refsum H: Plasma homocysteine - A risk factor for vascular disease: Plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989;114:473-501.
6. Welch GN, Loscalzo J: Homocysteine and atherosclerosis. N Engl J Med 1998;338:1042-1050.
7. Stein JH, McBride PE: Hyperhomocysteinemia and atherosclerotic vascular disease: Pathophysiology, screening and treatment. Arch Intern Med 1998;158:1301-1306.
8. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom Le, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Luis AC, Parrot-Rouland FM, Tan KS, Higgins I, Carcon D, Andria G: Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775-1781.
9. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG: Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-1398.
10. Moller J, Nielsen GM, Tvedegaard KC, Andresen NT, Jorgensen PE: A meta-analysis of cerebrovascualr disease and hyperhomocysteinemia. Scand J Clin Lab Invest 2000;60:491-499.
11. Evers S, Koch HG, Grotemeyer KH, Lange B, Deufel T, Ringelstein EB: Features, symptoms, and neurophysiological findings in stroke associated with hyperhomocysteinemia. Arch Neurol 1997;54:1276-1282.
12. Diaz-Arrastia R: Hyperhomocysteinemia: A new risk factor for Alzheimer's disease? Arch Neurol 1998;55:1407-1408.
13. Riggs KM, Spiro A 3rd, Tucker K, Rush D: Relations of vitamin B12, vitamin B6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr 1996;63:306-314.
14. 12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998;55:1449-1455.
15. Lehmann M, Gottfries CG, Regland B: Identification of cognitive impairment in the elderly: Homocysteine is an early marker. Dement Geriatr Cogn Disord 1999;10:12-20.
16. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, WolfPA: Plasma homocysteine as a risk factor for dementia and Alzheimer's Disease. N Engl J Med 2002;346:476-483.
17. Foulkes MA, Wolf PA, Price TR, Mohr JP, Hier DB: The stroke data bank: Design, methods, and baseline. Stroke 1988;19:547-554.
18. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
19. Nexo E, Engbaek F, Ueland PM, Westby C, O'Gorman P, Johnston C, Kase BF, Guttormsen AB, Alfheim I, McPartlin J, Smith D, Moller J, Rasmussen K, Clarke R, Scott JM, Refsum H: Evaluation of novel assays in clinical chemistry: Quantification of plasma total homocysteine. Clin Chem 2000;46:1150-1156.
20. Wang XL, Duarte N, Cai H, Adachi T, Sim AS, Cranney G, Wilcken DE: Relationship between total homocysteine polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population. Atherosclerosis 1999;146:133-140.
21. Nelson HE, Willison J: National Adult Reading Test (NART): Test Manual, ed 2. Windsor, NFER Nelson, 1991.
22. Yesavage JA, Brink TL, Rose TL, Lim O, Huang V, Adey M, Leirer VO: Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res 1982-83;17:37-49.
23. Briggs GG, Nebes RD: Patterns of hand preference in a student population. Cortex 1975;11:230-238.
24. Wechsler D: Wechsler Adult Intelligence Scale, revised. New York, Psychological Corporation, 1981.
25. Smith A: Symbol Digit Modalities Test. Los Angeles, Western Psychological Services, 1991.
26. Wechsler D: Wechsler Memory Scale, revised. San Antonio, Psychological Corporation, 1987.
27. Kaplan EF, Goodglass H, Weintraub S: The Boston Naming Test, ed 2. Philadelphia, Lea & Febiger, 1978.
28. Mack WJ, Freed DM, Williams BW, Henderson VW: Boston Naming Test: Shortened version for use in Alzheimer's disease. J Gerontol 1992;47:164-168.
29. DeRenzi E, Vignolo LA: The Token Test: A sensitive test to detect disturbances in aphasics. Brain 1962;85:665-678.
30. Spreen O, Strauss E: A Compendium of Neuropsychological Tests. Administration, Norms and Commentary, ed 2. New York, Oxford University Press, 1998.
31. Strub RL, Black FW: Mental Status Examination in Neurology, ed 2. Philadelphia, Davis, 1985.
32. Benton AL, Hamsher K deS, Varney NR, Spreen O: Contributions to Neuropsychological Assessment. New York, Oxford University Press, 1983.
33. Kertesz A: Western Aphasia Battery. San Antonio, Psychological Corporation, 1982.
34. Mattis S: Dementia Rating Scale (DRS). Odessa, Psychological Assessment Resources, 1988.
35. Goldstein KH, Sheerer M: Abstract and concrete behaviour: An experimental study with special tests. Psycholog Monogr 1941;53:239.
36. Tombaugh TN, Kozak J, Rees L: Normative data for the controlled oral word association test, pers commun, 1996; in Spreen and Strauss [30].
37. Reitan RM, Wolfson D: The Halstead-Reitan Neuropsychological Test Battery. Tucson, Neuropsychology Press, 1985.
38. Ivnik RJ, Malec,JF, Smith GE, Tangelos EG, Peterson EG, Kokmen E, Kurland LT: Mayo's Older Americans Normative Studies: WAIS-R norms for ages 56 to 97. Clin Neuropsychol 1992;6(suppl):1-30.
39. Ivnik RJ, Malec JF, Smith GE, Tangelos EG, Peterson EG, Kokmen E, Kurland LT: Mayo's Older Americans Normative Studies: WMS-R norms for ages 56 to 94. Clin Neuropsychol 1992;6(suppl):49-82.
40. Ivnik RJ, Malec JF, Smith GE: Neuropsychological tests' norms above age 55: COWAT, BNT, MAE Token, WRAT-R Reading, AMNART, STROOP, TMT and JLO. Clin Neuropsychol 1996;10:262-278.
41. Ryan JJ, Paolo AM: A screening procedure for estimating premorbid intelligence in the elderly. Clin Neuropsychol 1992;6:53-62.
42. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA: MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987;149:351-356.
43. Victoroff J, Mack WJ, Grafton ST, Schreiber SS, Chui HC: A method to improve interrater reliability of visual inspection of brain MRI scans in dementia. Neurology 1994;44:2267-2276.
44. Fassbender K, Mielke O, Bertsch T, Nafe B, Froschen S, Hennerici M: Homocysteine in cerebral macroangiography and microangiopathy. Lancet 1999;353:1586-1587.
45. Sachdev P, Valenzuela M, Wang XL, Looi JCL, Brodaty H: Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals. Neurology 2002;58:1539-1541.
46. Lindgren A, Brattstrom L, Norrving B, Hultberg B, Andersson A, Johansson BB: Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995;26:795-800.
47. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H: Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998;13:235-239.
48. Diaz-Arrastia R: Homocysteine and neurologic disease. Arch Neurol 2000;57:1422-1427.
49. Lipton SA, Kim WK, Choi YB, Kumar S, D'Emilia DM, Raydu PV, Arnelle DR, Stamler JS: Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 1997;94:5923-5928.
50. Beal MF, Swartz KJ, Finn SF, Mazurek MF, Kowall NW: Neurochemical characterization of excitotoxin lesions in the cerebral cortex. J Neurosci 1991;11:147-158.
51. Kruman II, Culmsee C, Chan SL, Kurman Y, Guo Z, Penix L, Mattson MP: Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000;20:6920-6926.